Get the Stockscreener App
1.60
1.91%
0.03
After Hours:
1.59
-0.01
-0.63%
Aptevo Therapeutics Inc stock is traded at $1.60, with a volume of 1.91M.
It is up +1.91% in the last 24 hours and up +8.84% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$1.57
Open:
$1.61
24h Volume:
1.91M
Relative Volume:
0.38
Market Cap:
$5.26M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0165
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
+13.48%
1M Performance:
+8.84%
6M Performance:
-92.08%
1Y Performance:
-98.51%
1-Day Range:
$1.50
$1.65
1-Week Range:
$1.50
$1.98
52-Week Range:
$1.32
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.60 | 21.68M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Tools to assess Aptevo Therapeutics Inc.’s risk profileJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
Using portfolio simulators with Aptevo Therapeutics Inc. includedEarnings Performance Report & Weekly Stock Performance Updates - newser.com
Why Aptevo Therapeutics Inc. stock appeals to analystsJuly 2025 Highlights & Community Supported Trade Ideas - newser.com
Why Aptevo Therapeutics Inc. stock remains a top recommendationJuly 2025 Trends & AI Driven Price Forecasts - newser.com
Why Aptevo Therapeutics Inc. stock remains on watchlists2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Top chart patterns to watch in Aptevo Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Aptevo Therapeutics Inc. (APVO) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
How sustainable is Aptevo Therapeutics Inc. stock dividend payoutJuly 2025 Volume & Free Community Supported Trade Ideas - newser.com
How to forecast Aptevo Therapeutics Inc. trends using time seriesJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - newser.com
Does Aptevo Therapeutics Inc. show high probability of reboundWeekly Market Report & Low Volatility Stock Recommendations - newser.com
Is Aptevo Therapeutics Inc. (AP81) stock inflation resilientWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com
Relative strength of Aptevo Therapeutics Inc. in sector analysisChart Signals & Stock Timing and Entry Methods - newser.com
What’s the recovery path for long term holders of Aptevo Therapeutics Inc.July 2025 Update & Consistent Return Strategy Ideas - newser.com
Will Aptevo Therapeutics Inc. stock outperform international peers2025 Top Gainers & High Win Rate Trade Tips - newser.com
Why analysts raise outlook for Aptevo Therapeutics Inc. (AP81) stockJuly 2025 WrapUp & Weekly Setup with ROI Potential - newser.com
What MACD signals say about Aptevo Therapeutics Inc.July 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - ACCESS Newswire
Interim RAINIER results: Aptevo to present Phase 1b/2 AML data at ASH, SITC, BIO-Europe and ROTH this fall - Stock Titan
APVO Stock Soars After Impressive Trial Results - StocksToTrade
APVO Stock Skyrockets: What’s Fueling the Growth? - timothysykes.com
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga
Advanced analytics toolkit walkthrough for Aptevo Therapeutics Inc.July 2025 Snapshot & Target Return Focused Picks - newser.com
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Will Aptevo Therapeutics Inc. stock recover faster than marketRate Cut & Fast Entry Momentum Alerts - newser.com
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):